{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:58:15Z","timestamp":1792432695216,"version":"4.5.0"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["1 R21 OD026618"],"award-info":[{"award-number":["1 R21 OD026618"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM125503"],"award-info":[{"award-number":["P20GM125503"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Multiple myeloma (MM) is a clonal B-cell disorder characterized by the proliferation of malignant plasma cells (PCs) in the bone marrow, the presence of monoclonal serum immunoglobulin, and osteolytic lesions. It is the second most common hematological malignancy and considered an incurable disease despite significant treatment improvements. MM bone disease (MMBD) is defined as the presence of one or more osteolytic bone lesions or diffused osteoporosis with compression fracture attributable to the underlying clonal PC disorder. MMBD causes severe morbidity and increases mortality. Cumulative evidence shows that the interaction of MM cells and bone microenvironment plays a significant role in MM progression, suggesting that these interactions may be good targets for therapy. MM animal models have been developed and studied in various aspects of MM tumorigenesis. In particular, MMBD has been studied in various models, and each model has unique features. As the general features of MM animal models have been reviewed elsewhere, the current review will focus on the features of MMBD animal models.<\/jats:p>","DOI":"10.3389\/fgene.2021.640954","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T07:01:47Z","timestamp":1623049307000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Animal Models of Multiple Myeloma Bone Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Syed Hassan","family":"Mehdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Nafees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Jafar","family":"Mehdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Mashouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghoon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/asheducation-2002.1.214","article-title":"Multiple myeloma.","volume":"2002","author":"Anderson","year":"2002","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/sj\/thj\/6200052","article-title":"The 5TMM series: a useful in vivo mouse model of human multiple myeloma.","volume":"1","author":"Asosingh","year":"2000","journal-title":"Hematol. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.","volume":"124","author":"Azab","year":"2014","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.bbmt.2012.04.004","article-title":"Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.","volume":"18","author":"Bartee","year":"","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043298","article-title":"Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.","volume":"7","author":"Bartee","year":"","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.","volume":"29","author":"Bjorkstrand","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.","volume":"12","author":"Body","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","article-title":"Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients.","volume":"1","author":"Botta","year":"2017","journal-title":"Blood Adv."},{"key":"B11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling.","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041127","article-title":"Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.","volume":"7","author":"Buckle","year":"2012","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/leu.2010.300","article-title":"A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.","volume":"25","author":"Calimeri","year":"2011","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.exphem.2006.03.005","article-title":"CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD\/SCID mice.","volume":"34","author":"Carlo-Stella","year":"2006","journal-title":"Exp. Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","article-title":"The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.","volume":"11","author":"Carrasco","year":"2007","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1365-2249.1992.tb05845.x","article-title":"Human immunoglobulin production in immunodeficient mice: enhancement by immunosuppression of host and in vitro activation of human mononuclear cells.","volume":"90","author":"Cavacini","year":"1992","journal-title":"Clin. Exp. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.ejca.2006.02.016","article-title":"Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy.","volume":"42","author":"Chatterjee","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1172\/JCI20369","article-title":"Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.","volume":"113","author":"Cheung","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.","volume":"18","author":"Croucher","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"B23","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone.","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/srep30998","article-title":"Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss.","volume":"6","author":"Deshet-Unger","year":"2016","journal-title":"Sci. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1349-7006.2004.tb02487.x","article-title":"Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD\/SCID\/gammacnull mice.","volume":"95","author":"Dewan","year":"2004","journal-title":"Cancer Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1038\/480S38a","article-title":"Animal models: Towards a myeloma mouse.","volume":"480","author":"DeWeerdt","year":"2011","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/sj.leu.2402374","article-title":"IL-1\u03b2 expression in IgM monoclonal gammopathy and its relationship to multiple myeloma.","volume":"16","author":"Donovan","year":"2002","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","article-title":"Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.","volume":"118","author":"D\u2019Souza","year":"2011","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.","volume":"31","author":"Eda","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bone.2015.10.004","article-title":"Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods.","volume":"83","author":"Evans","year":"2016","journal-title":"Bone"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0139-7","article-title":"Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.","volume":"8","author":"Faict","year":"2018","journal-title":"Blood Cancer J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1242\/dmm.003160","article-title":"A murine model of myeloma that allows genetic manipulation of the host microenvironment.","volume":"2","author":"Fowler","year":"2009","journal-title":"Dis. Model Mech."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057641","article-title":"Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.","volume":"8","author":"Fryer","year":"2013","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2119\/molmed.2011.00178","article-title":"Therapeutic potential of SH2 domain-containing inositol-5\u2019-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.","volume":"18","author":"Fuhler","year":"2012","journal-title":"Mol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease.","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1002\/jbmr.3859","article-title":"TGFbeta Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.","volume":"34","author":"Green","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1182\/blood.v97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.","volume":"24","author":"Heath","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-05-2501","article-title":"MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.","volume":"12","author":"Hideshima","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3324\/haematol.2016.144477","article-title":"Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment.","volume":"101","author":"Hinge","year":"2016","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood.V94.11.3883","article-title":"Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.","volume":"94","author":"Hjertner","year":"1999","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ni907","article-title":"Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1.","volume":"4","author":"Iwakoshi","year":"2003","journal-title":"Nat. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2010.08.001","article-title":"Adhesive interactions: The multi-task biochemical toolbox of cancer cells.","volume":"20","author":"Katz","year":"2010","journal-title":"Semin. Cancer Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3324\/haematol.12261","article-title":"The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.","volume":"93","author":"Khong","year":"2008","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","first-page":"25593","DOI":"10.1074\/jbc.M113.480574","article-title":"The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.","volume":"288","author":"Kikuchi","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccr.2008.01.022","article-title":"Modeling multiple myeloma by AID-dependent conditional activation of MYC.","volume":"13","author":"Kuehl","year":"2008","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma.","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.","volume":"6","author":"Lawson","year":"","journal-title":"Nat. Commun."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119546","article-title":"NOD\/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.","volume":"10","author":"Lawson","year":"","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2141.2007.06742.x","article-title":"Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.","volume":"138","author":"Li","year":"2007","journal-title":"Br. J. Haematol."},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.1038\/bonekey.2015.142","article-title":"Preclinical animal models of multiple myeloma.","volume":"5","author":"Lwin","year":"2016","journal-title":"BoneKEy Rep."},{"key":"B60","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/bjc.1992.415","article-title":"A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL\/KaLwRij mouse.","volume":"66","author":"Manning","year":"1992","journal-title":"Br. J. Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031286","article-title":"Multiple Myeloma and Bone: The Fatal Interaction.","volume":"8","author":"Marino","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.306","article-title":"Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL\/MD5-1 or 5-azacytidine using syngeneic Vk\u2217MYC multiple myeloma.","volume":"4","author":"Matthews","year":"2013","journal-title":"Cell Death Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.2971269","article-title":"The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.","volume":"241","author":"McCune","year":"1988","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021811","article-title":"Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.","volume":"6","author":"Mirandola","year":"2011","journal-title":"PLoS One"},{"key":"B66","first-page":"6689","article-title":"Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID\/NOD in vivo model: biologic and clinical implications.","volume":"63","author":"Mitsiades","year":"2003","journal-title":"Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bbrc.2003.11.120","article-title":"Establishment of a new model of human multiple myeloma using NOD\/SCID\/gammac(null) (NOG) mice.","volume":"313","author":"Miyakawa","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115876","article-title":"Bone remineralization Of Lytic Lesions in Multiple Myeloma \u2013The Arkansas Experience.","volume":"2021","author":"Mohan","year":"2021","journal-title":"Bone"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/jbmr.3111","article-title":"Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.","volume":"32","author":"Mohan","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma.","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis.","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma.","volume":"291","author":"Mundy","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"B73","year":"2020","journal-title":"Cancer Stat Facts: Myeloma."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1038\/sj.leu.2404912","article-title":"Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.","volume":"21","author":"Neri","year":"2007","journal-title":"Leukemia"},{"key":"B75","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3606","article-title":"Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.","volume":"34","author":"Paton-Hough","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"B76","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V95.3.1056.003k26_1056_1065","article-title":"Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.","volume":"95","author":"Pilarski","year":"2000","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/14728210802676278","article-title":"Emerging therapies for multiple myeloma.","volume":"14","author":"Podar","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"B78","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00223-009-9284-0","article-title":"Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model.","volume":"85","author":"Postnov","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"B79","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma.","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/sj.leu.2404814","article-title":"A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer.","volume":"21","author":"Rabin","year":"2007","journal-title":"Leukemia"},{"key":"B81","first-page":"91","article-title":"Animal model of human disease. Benign monoclonal gammopathy (idiopathic paraproteinemia).","volume":"105","author":"Radl","year":"1981","journal-title":"Am. J. Pathol."},{"key":"B82","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y","article-title":"Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.","volume":"55","author":"Radl","year":"1985","journal-title":"Cancer"},{"key":"B83","first-page":"593","article-title":"Animal model of human disease. Multiple myeloma.","volume":"132","author":"Radl","year":"1988","journal-title":"Am. J. Pathol."},{"key":"B84","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4049\/jimmunol.122.2.609","article-title":"Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice.","volume":"122","author":"Radl","year":"1979","journal-title":"J. Immunol."},{"key":"B85","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma.","volume":"25","author":"Raje","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"B87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.V126.23.119.119","article-title":"Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden.","volume":"126","author":"Reagan","year":"2015","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jbmr.5650090522","article-title":"Interleukin\u22126 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone.","volume":"9","author":"Reddy","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061765","article-title":"Anti-VEGF drugs in the treatment of multiple myeloma patients.","volume":"9","author":"Ria","year":"2020","journal-title":"J. Clin. Med."},{"key":"B90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00223-017-0351-7","article-title":"New agents in the treatment of myeloma bone disease.","volume":"102","author":"Ring","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/sj.leu.2403774","article-title":"Maintained rules of development in a mouse B-cell tumor.","volume":"19","author":"Robbiani","year":"2005","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","article-title":"SDF-1 inhibition targets the bone marrow niche for cancer therapy.","volume":"9","author":"Roccaro","year":"2014","journal-title":"Cell Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease.","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"B94","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1365-2141.1999.01193.x","article-title":"Expression of interleukin\u22121\u03b2 and tumour necrosis factor\u2212\u03b1 in plasma cells from patients with multiple myeloma.","volume":"104","author":"Sati","year":"1999","journal-title":"Br. J. Haematol."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1186\/ar2171","article-title":"Clinical development of anti-RANKL therapy.","author":"Schwarz","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"B96","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2002.03898.x","article-title":"Hepatocyte growth factor in myeloma patients treated with high\u2212dose chemotherapy.","volume":"119","author":"Seidel","year":"2002","journal-title":"Br. J. Haematol."},{"key":"B97","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease.","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/leu.2008.81","article-title":"Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.","volume":"22","author":"Shammas","year":"2008","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: Pathophysiology and management.","volume":"2","author":"Silbermann","year":"2013","journal-title":"J. Bone Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting.","volume":"111","author":"Swami","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B101","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood-2005-01-0373","article-title":"A clinically relevant SCID-hu in vivo model of human multiple myeloma.","volume":"106","author":"Tassone","year":"2005","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ejca.2006.04.005","article-title":"Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?","volume":"42","author":"Tassone","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1046\/j.1365-2141.2003.04712.x","article-title":"New insights into the pathophysiology and management of bone disease in multiple myeloma.","volume":"123","author":"Terpos","year":"2003","journal-title":"Br. J. Haematol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1158\/1078-0432.CCR-11-3085","article-title":"Reovirus as a viable therapeutic option for the treatment of multiple myeloma.","volume":"18","author":"Thirukkumaran","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","article-title":"Fractures and survival in multiple myeloma: results from a population-based study.","volume":"105","author":"Thorsteinsdottir","year":"2020","journal-title":"Haematologica"},{"key":"B108","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/bjh.12226","article-title":"Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.","volume":"161","author":"Udi","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B110","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V90.2.754","article-title":"The development of a model for the homing of multiple myeloma cells to human bone marrow.","volume":"90","author":"Urashima","year":"1997","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V88.6.2219.bloodjournal8862219","article-title":"Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein.","volume":"88","author":"Urashima","year":"1996","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood.V93.1.235","article-title":"Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells.","volume":"93","author":"Vanderkerken","year":"1999","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse.","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br. J. Cancer"},{"key":"B114","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.2004.05143.x","article-title":"New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia.","volume":"127","author":"Voskaridou","year":"2004","journal-title":"Br. J. Haematol."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL\u2013RANK\u2013OPG system in immunity, bone, and beyond.","volume":"5","author":"Walsh","year":"2014","journal-title":"Front. Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients.","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00262-006-0196-9","article-title":"Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.","volume":"56","author":"Wu","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"B118","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbrc.2012.10.071","article-title":"Dll1\/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.","volume":"428","author":"Xu","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B119","doi-asserted-by":"publisher","first-page":"6901","DOI":"10.1158\/0008-5472.CAN-16-0517","article-title":"Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.","volume":"76","author":"Xu","year":"2016","journal-title":"Cancer Res."},{"key":"B120","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.","volume":"92","author":"Yaccoby","year":"1998","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br. J. Haematol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1182\/blood-2014-03-563981","article-title":"Pyk2 promotes tumor progression in multiple myeloma.","volume":"124","author":"Zhang","year":"2014","journal-title":"Blood"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.640954\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T16:05:43Z","timestamp":1699113943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.640954\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":123,"alternative-id":["10.3389\/fgene.2021.640954"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.640954","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"article-number":"640954"}}